Theralase Technologies Stock Today
| TLT Stock | CAD 0.19 0.01 5.00% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Theralase Technologies is selling for under 0.19 as of the 22nd of March 2025; that is 5% down since the beginning of the trading day. The stock's lowest day price was 0.19. Theralase Technologies has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | Category Healthcare | Classification Health Care |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. The company has 245.54 M outstanding shares of which 42.79 K shares are at this time shorted by private and institutional investors with about 0.06 days to cover all short positions. More on Theralase Technologies
Moving together with Theralase Stock
Moving against Theralase Stock
Theralase Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Theralase Technologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Theralase Technologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Roger DumoulinWhite | ||||
| Thematic Idea | IT (View all Themes) | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, IT, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare, Computing (View all Sectors) | ||||
Theralase Technologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Theralase Technologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsTheralase Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theralase Technologies' financial leverage. It provides some insight into what part of Theralase Technologies' total assets is financed by creditors.
| |||||
Theralase Technologies (TLT) is traded on TSX Venture Exchange in Canada and employs 7 people. Theralase Technologies is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 66.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theralase Technologies's market, we take the total number of its shares issued and multiply it by Theralase Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Theralase Technologies classifies itself under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 245.54 M outstanding shares of which 42.79 K shares are at this time shorted by private and institutional investors with about 0.06 days to cover all short positions.
Theralase Technologies has accumulated about 1.67 M in cash with (3.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Theralase Technologies Probability Of Bankruptcy
Ownership AllocationTheralase Technologies shows a total of 245.54 Million outstanding shares. Theralase Technologies has 8.7 % of its outstanding shares held by insiders and 0.0 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Theralase Ownership Details
Theralase Technologies Risk Profiles
Although Theralase Technologies' alpha and beta are two of the key measurements used to evaluate Theralase Technologies' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.4 | |||
| Standard Deviation | 4.59 | |||
| Variance | 21.07 | |||
| Risk Adjusted Performance | (0.06) |
Theralase Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Theralase Technologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Theralase Technologies Corporate Management
Elected by the shareholders, the Theralase Technologies' board of directors comprises two types of representatives: Theralase Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theralase. The board's role is to monitor Theralase Technologies' management team and ensure that shareholders' interests are well served. Theralase Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theralase Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lori Leach | Marketing Consultant | Profile | |
| Terry DVM | Equine Consultant | Profile | |
| DSc MD | Chief CEO | Profile | |
| Vaughn Wyant | Marketing Consultant | Profile | |
| Kristina CPA | CFO Director | Profile |
Additional Tools for Theralase Stock Analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.